Compare · DNA vs GILD
DNA vs GILD
Side-by-side comparison of Ginkgo Bioworks Holdings Inc. (DNA) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNA and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $171.56B, about 392.7x DNA ($436.9M).
- Over the past year, DNA is down 48.4% and GILD is up 16.9% - GILD leads by 65.4 points.
- GILD has been more active in the news (12 items in the past 4 weeks vs 8 for DNA).
- GILD has more recent analyst coverage (25 ratings vs 18 for DNA).
- Company
- Ginkgo Bioworks Holdings Inc.
- Gilead Sciences Inc.
- Price
- $6.78-6.16%
- $138.36+0.21%
- Market cap
- $436.9M
- $171.56B
- 1M return
- -18.21%
- +1.53%
- 1Y return
- -48.44%
- +16.93%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 8
- 12
- Recent ratings
- 18
- 25
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest DNA
- Ginkgo Bioworks downgraded by TD Cowen with a new price target
- SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4 filed by Large owner Canton Barry
- SEC Form 4 filed by Officer Shetty Reshma P.
- SEC Form 4 filed by Officer Kelly Jason R
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Officer Coen Steven P. converted options into 1,486 shares and sold $5,943 worth of shares (752 units at $7.90), increasing direct ownership by 1% to 51,438 units (SEC Form 4) (tax liability)
- SEC Form 4 filed by Director Henry Christian O
- SEC Form 4 filed by Director Fubini Ross
Latest GILD
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Gilead Sciences Announces Second Quarter 2026 Financial Results
- SEC Form 13F-HR filed by Gilead Sciences Inc.
- FDA Approval for VEKLURY issued to GILEAD SCIENCES INC
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer